2012年3月
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma
JOURNAL OF GASTROENTEROLOGY
- 巻
- 47
- 号
- 3
- 開始ページ
- 343
- 終了ページ
- 346
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1007/s00535-011-0511-x
- 出版者・発行元
- SPRINGER TOKYO
Background There is no standard therapy for patients with transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). This study examined whether evaluating the tumor effect (TE) at 1 week after TACE was useful for predicting refractoriness to TACE.
Methods We performed a historical cohort study involving 54 patients and 119 tumors. TE was evaluated at 1 week and 3 months after TACE, and an overall evaluation was also performed at 3 months based on the response evaluation criteria in cancer of the liver.
Results Among 45 tumors evaluated as TE2 at 1 week, 43 tumors (95.6%) were classified as TE1 or TE2 at 3 months. Of the 24 patients whose tumors were categorized as TE2 at 1 week, none achieved a complete or partial response.
Conclusions Evaluating the TE at 1 week after TACE is useful for the early diagnosis of TACE-refractory HCC and allows alternative treatment options, such as sorafenib, to be employed before the disease progresses.
Methods We performed a historical cohort study involving 54 patients and 119 tumors. TE was evaluated at 1 week and 3 months after TACE, and an overall evaluation was also performed at 3 months based on the response evaluation criteria in cancer of the liver.
Results Among 45 tumors evaluated as TE2 at 1 week, 43 tumors (95.6%) were classified as TE1 or TE2 at 3 months. Of the 24 patients whose tumors were categorized as TE2 at 1 week, none achieved a complete or partial response.
Conclusions Evaluating the TE at 1 week after TACE is useful for the early diagnosis of TACE-refractory HCC and allows alternative treatment options, such as sorafenib, to be employed before the disease progresses.
- リンク情報
-
- DOI
- https://doi.org/10.1007/s00535-011-0511-x
- CiNii Articles
- http://ci.nii.ac.jp/naid/10030560280
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/22183859
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000303455700013&DestApp=WOS_CPL
- ID情報
-
- DOI : 10.1007/s00535-011-0511-x
- ISSN : 0944-1174
- eISSN : 1435-5922
- CiNii Articles ID : 10030560280
- PubMed ID : 22183859
- Web of Science ID : WOS:000303455700013